24th Apr 2025 15:55
Hikma Pharmaceuticals PLC
Results of 2025 Annual General Meeting
LONDON, 24 April 2025 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (the 'Company' or 'Hikma') announces that its Annual General Meeting ('AGM') was held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN earlier today (24 April 2025) and commenced at 11.30 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 (inclusive) were passed as ordinary resolutions and Resolutions 17 to 20 (inclusive) were passed as special resolutions. Resolutions 21 to 22 (inclusive) were passed as ordinary resolutions on which only Independent Shareholders (that is, excluding members of the Darhold Concert Party, in accordance with the City Code on Takeovers and Mergers) were entitled to vote.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism. Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Notice of Meeting dated 19 March 2025.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the Notice of Meeting dated 19 March 2025) is set out below. The number of Ordinary Shares in issue at the close of business on 22 April 2025 was 234,719,686. At that time there were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 221,886,453.
Resolution | Votes For | % of Eligible Votes | Votes Against | % of Eligible Votes | Total Votes Cast | Total votes cast as a % of ISC1 | Withheld2 |
1. To receive the 2024 report and accounts | 165,916,947 | 99.98% | 25,032 | 0.02% | 165,941,979 | 74.79% | 1,306,504 |
2. To approve a final dividend of 48 cents per share | 167,236,391 | 99.99% | 101 | 0.01% | 167,236,492 | 75.37% | 11,991 |
3. To re-appoint PricewaterhouseCoopers LLP as Auditor | 165,736,140 | 99.80% | 324,240 | 0.20% | 166,060,380 | 74.84% | 1,188,103 |
4. To authorise the Audit Committee to determine the remuneration of the Auditor | 166,976,846 | 99.84% | 259,630 | 0.16% | 167,236,476 | 75.37% | 12,007 |
5. To re-elect Said Darwazah as a Director | 159,872,112 | 96.63% | 5,581,855 | 3.37% | 165,453,967 | 74.57% | 1,794,516 |
6. To re-elect Riad Mishlawi as a Director | 165,620,901 | 99.04% | 1,612,530 | 0.96% | 167,233,431 | 75.37% | 15,052 |
7. To re-elect Mazen Darwazah as a Director | 158,508,255 | 95.06% | 8,244,567 | 4.94% | 166,752,822 | 75.15% | 495,661 |
8. To re-elect Victoria Hull as a Director | 164,823,607 | 98.84% | 1,929,924 | 1.16% | 166,753,531 | 75.15% | 494,952 |
9. To re-elect Ali Al-Husry as a Director | 165,206,365 | 98.86% | 1,903,076 | 1.14% | 167,109,441 | 75.31% | 139,042 |
10. To re-elect Nina Henderson as a Director | 166,343,333 | 99.47% | 891,330 | 0.53% | 167,234,663 | 75.37% | 13,820 |
11. To re-elect Cynthia Flowers as a Director | 166,327,864 | 99.46% | 906,799 | 0.54% | 167,234,663 | 75.37% | 13,820 |
12. To re-elect Douglas Hurt as a Director | 166,338,974 | 99.47% | 894,533 | 0.53% | 167,233,507 | 75.37% | 14,976 |
13. To re-elect Laura Balan as a Director | 166,404,839 | 99.50% | 829,824 | 0.50% | 167,234,663 | 75.37% | 13,820 |
14. To re-elect Dr Deneen Vojta as a Director | 166,339,842 | 99.46% | 894,796 | 0.54% | 167,234,638 | 75.37% | 13,845 |
15. To receive and approve the annual report on Remuneration | 165,314,532 | 99.55% | 745,734 | 0.45% | 166,060,266 | 74.84% | 1,188,217 |
16. To authorise the Directors to allot shares and grant rights to subscribe for shares | 161,367,208 | 96.49% | 5,868,306 | 3.51% | 167,235,514 | 75.37% | 12,969 |
17. To authorise the disapplication of pre-emption rights (General) | 159,795,080 | 95.55% | 7,438,019 | 4.45% | 167,233,099 | 75.37% | 15,384 |
18. To authorise the disapplication of pre-emption rights (Acquisition or Capital Investment) | 150,608,461 | 90.06% | 16,626,673 | 9.94% | 167,235,134 | 75.37% | 13,349 |
19. To authorise the Company to purchase Ordinary Shares | 165,666,195 | 99.21% | 1,314,296 | 0.79% | 166,980,491 | 75.25% | 267,992 |
20. To authorise the Company to hold general meetings on not less than 14 clear days' notice | 161,269,635 | 96.43% | 5,966,422 | 3.57% | 167,236,057 | 75.37% | 12,426 |
21. To approve the Rule 9 Waiver (Buyback Waiver)3 | 103,445,950 | 93.41% | 7,303,834 | 6.59% | 110,749,784 | 49.91% | 3,164,163 |
22. To approve the Rule 9 Waiver (2026 Awards Waiver)3 | 105,601,900 | 95.35% | 5,145,069 | 4.65% | 110,746,969 | 49.91% | 3,166,978 |
1 Issued Ordinary Share capital of the Company (excluding treasury shares).
2 A "withheld" vote is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
3 In order to comply with the City Code on Takeovers and Mergers, only the votes cast by the independent shareholders were counted for the purposes of Resolutions 21 to 22.
Declaration of final dividend
The dividend of 48 cents per share will be paid on 1 May 2025 to shareholders on the register at the close of business on 21 March 2025. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.29 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.708JD.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Helen Middlemist Group Company Secretary | +44 20 7399 2670 |
Related Shares:
Hikma Pharmaceuticals